PDS Biotech has reported final phase 2 data on PDS0101 in the tough-to-treat head and neck cancer setting, linking a combination of the immunotherapy and Keytruda to median overall survival (OS) of 39 ...

PDS0101 and pembrolizumab combination achieved a median overall survival of 39.3 months in HPV16-positive head and neck cancer patients with a CPS of at least 1. The VERSATILE-002 trial showed ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

The Chargers waived Vidal on Tuesday. The 2024 sixth-rounder entered training camp in the mix for a depth role behind Najee Harris (eye) and rookie Omarion Hampton. Vidal wasn't the most efficient ...

The following is an excerpt from Passionate Outlier: Gay Writers and Allies on Their Work by Frank Pizzoli and now available from Rebel Satori Press. Subscribe to our newsletter for a refreshing ...

After many U.S. biopharma companies posted sales declines in the first quarter, the domestic pharma industry largely bounced back to growth in the second quarter. In this episode of "The Top Line," ...

The advancement of Pfizer’s antibody-drug conjugate portfolio has not spared the former Seagen site—and those who helped develop the therapies—from layoffs. Pfizer is laying off 100 employees in ...

The FDA’s recent rebuff of Replimune’s melanoma candidate has rippled across the industry, prompting one biotech to shutter a clinical trial evaluating a similar drug. Krystal Biotech has discontinued ...